Myriad Genetics, Inc. (NASDAQ:MYGN) – Equities research analysts at Leerink Swann cut their Q1 2019 EPS estimates for shares of Myriad Genetics in a research report issued to clients and investors on Wednesday, September 19th. Leerink Swann analyst P. Souda now expects that the company will post earnings of $0.21 per share for the quarter, down from their previous estimate of $0.24. Leerink Swann also issued estimates for Myriad Genetics’ Q3 2019 earnings at $0.42 EPS, Q4 2019 earnings at $0.43 EPS and FY2019 earnings at $1.41 EPS.

Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings results on Tuesday, August 21st. The company reported $0.38 EPS for the quarter, beating the Zacks’ consensus estimate of $0.33 by $0.05. Myriad Genetics had a return on equity of 9.78% and a net margin of 17.69%. The company had revenue of $200.90 million during the quarter, compared to analysts’ expectations of $195.93 million. During the same period in the prior year, the company earned $0.30 EPS. Myriad Genetics’s revenue was up .7% compared to the same quarter last year.

A number of other brokerages have also recently commented on MYGN. Barclays increased their price target on Myriad Genetics from $35.00 to $38.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 22nd. Zacks Investment Research upgraded Myriad Genetics from a “hold” rating to a “buy” rating and set a $54.00 price target for the company in a research note on Friday, August 24th. Piper Jaffray Companies increased their price target on Myriad Genetics to $38.00 and gave the company a “neutral” rating in a research note on Wednesday, August 22nd. ValuEngine cut Myriad Genetics from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, September 12th. Finally, BidaskClub upgraded Myriad Genetics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 29th. Four investment analysts have rated the stock with a sell rating, three have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Myriad Genetics has a consensus rating of “Hold” and an average price target of $39.10.

Shares of MYGN opened at $46.65 on Monday. Myriad Genetics has a 52 week low of $27.23 and a 52 week high of $50.44. The firm has a market capitalization of $3.28 billion, a PE ratio of 39.62, a PEG ratio of 3.16 and a beta of 0.43. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.19 and a quick ratio of 2.86.

In related news, insider Mark Christopher Capone sold 80,000 shares of the firm’s stock in a transaction on Wednesday, July 11th. The stock was sold at an average price of $41.00, for a total transaction of $3,280,000.00. Following the completion of the transaction, the insider now directly owns 184,948 shares of the company’s stock, valued at approximately $7,582,868. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director John T. Henderson sold 30,000 shares of the firm’s stock in a transaction on Wednesday, July 11th. The stock was sold at an average price of $42.06, for a total value of $1,261,800.00. Following the transaction, the director now directly owns 59,743 shares of the company’s stock, valued at $2,512,790.58. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 180,672 shares of company stock valued at $7,572,215. 6.70% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. Royal Bank of Canada raised its position in Myriad Genetics by 59.5% during the 1st quarter. Royal Bank of Canada now owns 4,597 shares of the company’s stock worth $136,000 after purchasing an additional 1,715 shares during the last quarter. Robecosam AG raised its position in shares of Myriad Genetics by 39.8% in the 2nd quarter. Robecosam AG now owns 4,193 shares of the company’s stock worth $156,000 after acquiring an additional 1,193 shares in the last quarter. Asset Management One Co. Ltd. bought a new position in shares of Myriad Genetics in the 1st quarter worth about $176,000. Victory Capital Management Inc. bought a new position in shares of Myriad Genetics in the 1st quarter worth about $185,000. Finally, Commonwealth Equity Services LLC bought a new position in shares of Myriad Genetics in the 2nd quarter worth about $205,000.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Featured Story: Return on Investment (ROI)

Earnings History and Estimates for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.